Download Immune Strategies For Gastrointestinal Cancer full books in PDF, epub, and Kindle. Read online Immune Strategies For Gastrointestinal Cancer ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
This book provides an overview of the available evidence surrounding immunotherapy in gastrointestinal cancers, and discusses its future place in clinical practice. Immunotherapy has celebrated some astonishing therapeutic successes in a variety of cancer types and is becoming increasingly relevant in daily clinical practice. Currently, the predominant class of immunotherapeutic drugs is the so-called checkpoint inhibitors, which disengage the physiological brakes on the immune system, enabling a more effective anti-cancer immune response. Malignancies of the gastrointestinal tract, which account for the majority of cancer cases worldwide, are a major cause of morbidity and mortality, creating an urgent need for more effective therapies. A large number of clinical trials have evaluated the efficacy of cancer immunotherapy in gastrointestinal malignancies and demonstrated its potential in certain subsets of patients. This book will appeal to a wide readership, including oncologists, health care professionals in general and biomedical scientists.
Book Synopsis Immune Strategies for Gastrointestinal Cancer by : Markus Moehler
Download or read book Immune Strategies for Gastrointestinal Cancer written by Markus Moehler and published by Springer Nature. This book was released on 2023-12-31 with total page 291 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides an overview of the available evidence surrounding immunotherapy in gastrointestinal cancers, and discusses its future place in clinical practice. Immunotherapy has celebrated some astonishing therapeutic successes in a variety of cancer types and is becoming increasingly relevant in daily clinical practice. Currently, the predominant class of immunotherapeutic drugs is the so-called checkpoint inhibitors, which disengage the physiological brakes on the immune system, enabling a more effective anti-cancer immune response. Malignancies of the gastrointestinal tract, which account for the majority of cancer cases worldwide, are a major cause of morbidity and mortality, creating an urgent need for more effective therapies. A large number of clinical trials have evaluated the efficacy of cancer immunotherapy in gastrointestinal malignancies and demonstrated its potential in certain subsets of patients. This book will appeal to a wide readership, including oncologists, health care professionals in general and biomedical scientists.
Gastrointestinal (GI) cancers, including gastric cancer, colon cancer, liver cancer, esophageal cancer, and pancreatic cancer, seriously threaten the health of human beings worldwide with a high rate of morbidity and mortality. The clinical successes achieved with immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 have opened a new cancer therapy era and brought new hope to cancer patients. However, the overall response rate (ORR) of ICI monotherapy in the non-selective population is only about 20%, in which some patients subsequently develop immunotherapy resistance. Moreover, the remaining 70-80% of patients displayed primary resistance to ICIs, and a few patients even experienced hyper progression disease (HPD). Although PD-L1 expression, mismatch repair deficient (MMRd), high tumor mutational burden (TMB-H) , high homologous recombination deficiency (HRD), and tumor infiltrated immune cells (TILs) are known as effective biomarkers for immunotherapy, growing studies have reported that ICIs could not improve the OS of all patients with PD-L1 expression higher than 50%, and the ORR of MSI-H patients was only about 60%, whereas some patients with low PD-L1 expression or MSS could still benefit from immunotherapy, indicating the complexity of ICI resistance. Therefore, it is of great importance and significance to explore the prediction biomarkers for primary or acquired immunotherapy resistance and elucidate their underlying molecular mechanisms and develop reversal strategies. Due to the multiple steps of the cancer immune cycle and complex immune microenvironment, any disorders of immune cell infiltration or T cell activation, such as lack of antigens and/or their presentation, lack of response to antigen presentation, and T cell priming, could contribute to ICI resistance. The combination with anti-angiogenesis therapy, radiotherapy, chemotherapy, and other ICIs has improved the efficacy of ICI therapy to some extent in the clinic. Although numerous studies related to ICI resistance were reported in GI cancers, due to the strong spatial/temporal heterogeneity and the complex immune microenvironment in different kinds of GI cancers and different individuals, many questions about ICI resistance and reversal strategies remain unsolved. The aim of this Research Topic is to provide a forum to exhibit the latest research achievement related to the exploration of biomarkers for immunotherapy resistance including HPD and the underlying molecular mechanisms, as well as the development of reversal strategies in GI cancers. We hope this Research Topic will lead to a better understanding of precision cancer immunotherapy and provide useful clues for clinical application to benefit more GI cancer patients with immunotherapy.
Book Synopsis Gastrointestinal Cancer Immunotherapy: from Drug Resistance Mechanisms to Overcoming Strategies by : Xiaofang Che
Download or read book Gastrointestinal Cancer Immunotherapy: from Drug Resistance Mechanisms to Overcoming Strategies written by Xiaofang Che and published by Frontiers Media SA. This book was released on 2023-06-15 with total page 212 pages. Available in PDF, EPUB and Kindle. Book excerpt: Gastrointestinal (GI) cancers, including gastric cancer, colon cancer, liver cancer, esophageal cancer, and pancreatic cancer, seriously threaten the health of human beings worldwide with a high rate of morbidity and mortality. The clinical successes achieved with immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 have opened a new cancer therapy era and brought new hope to cancer patients. However, the overall response rate (ORR) of ICI monotherapy in the non-selective population is only about 20%, in which some patients subsequently develop immunotherapy resistance. Moreover, the remaining 70-80% of patients displayed primary resistance to ICIs, and a few patients even experienced hyper progression disease (HPD). Although PD-L1 expression, mismatch repair deficient (MMRd), high tumor mutational burden (TMB-H) , high homologous recombination deficiency (HRD), and tumor infiltrated immune cells (TILs) are known as effective biomarkers for immunotherapy, growing studies have reported that ICIs could not improve the OS of all patients with PD-L1 expression higher than 50%, and the ORR of MSI-H patients was only about 60%, whereas some patients with low PD-L1 expression or MSS could still benefit from immunotherapy, indicating the complexity of ICI resistance. Therefore, it is of great importance and significance to explore the prediction biomarkers for primary or acquired immunotherapy resistance and elucidate their underlying molecular mechanisms and develop reversal strategies. Due to the multiple steps of the cancer immune cycle and complex immune microenvironment, any disorders of immune cell infiltration or T cell activation, such as lack of antigens and/or their presentation, lack of response to antigen presentation, and T cell priming, could contribute to ICI resistance. The combination with anti-angiogenesis therapy, radiotherapy, chemotherapy, and other ICIs has improved the efficacy of ICI therapy to some extent in the clinic. Although numerous studies related to ICI resistance were reported in GI cancers, due to the strong spatial/temporal heterogeneity and the complex immune microenvironment in different kinds of GI cancers and different individuals, many questions about ICI resistance and reversal strategies remain unsolved. The aim of this Research Topic is to provide a forum to exhibit the latest research achievement related to the exploration of biomarkers for immunotherapy resistance including HPD and the underlying molecular mechanisms, as well as the development of reversal strategies in GI cancers. We hope this Research Topic will lead to a better understanding of precision cancer immunotherapy and provide useful clues for clinical application to benefit more GI cancer patients with immunotherapy.
This book reviews current immunotherapeutic strategies for gastrointestinal (GI) malignancies, including immune composition, immune checkpoint inhibitors, cell therapy, and peptide vaccines used to protect against esophageal, gastric, hepato-biliary, pancreatic and colorectal cancers. It also discusses the current challenges of using immunotherapy for the treatment of gastrointestinal malignancies. The book reviews highly sensitive and specific immunomarkers for the detection of GI malignancies, and examines therapeutic vaccines and the major cytokines involved in GI immunotherapy, as well as their basic biology and clinical applications. In closing, the book explores various aspects of computational biology for the detection and treatment of GI malignancies.
Book Synopsis Immunotherapy for Gastrointestinal Malignancies by : Ramakrishna Vadde
Download or read book Immunotherapy for Gastrointestinal Malignancies written by Ramakrishna Vadde and published by Springer Nature. This book was released on 2021-01-31 with total page 257 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book reviews current immunotherapeutic strategies for gastrointestinal (GI) malignancies, including immune composition, immune checkpoint inhibitors, cell therapy, and peptide vaccines used to protect against esophageal, gastric, hepato-biliary, pancreatic and colorectal cancers. It also discusses the current challenges of using immunotherapy for the treatment of gastrointestinal malignancies. The book reviews highly sensitive and specific immunomarkers for the detection of GI malignancies, and examines therapeutic vaccines and the major cytokines involved in GI immunotherapy, as well as their basic biology and clinical applications. In closing, the book explores various aspects of computational biology for the detection and treatment of GI malignancies.
Currently, the treatment options for gastrointestinal malignancies mainly include surgery, chemotherapy, radiotherapy, and molecular targeted therapy, etc. Drug therapy is one of the main treatments for patients with advanced stages, but the efficacy of chemotherapy seems to have reached a plateau, and the progress of traditional molecular targeted therapy is relatively slow. In addition, the benefits of the current chemotherapy combined with targeted therapy for patients with advanced stages of gastrointestinal malignancies are still not satisfactory. Tumor immunotherapy is an emerging therapeutic approach and is a current research hotspot, and there are hopes that immunotherapy can help further improve the prognosis and quality of life for patients with gastrointestinal malignancies. At the same time, potential targets of immunotherapeutic drugs and prognostic biomarkers for gastrointestinal malignancies have been less studied than other common cancers, such as lung cancer. Prognostic biomarker studies are the beginning of exploring new drug targets and revealing potential mechanisms of tumor progression. Immunotherapies, particularly PD1 or PD-L1 antagonists, have demonstrated effective therapeutic efficacy against various types of cancer. To date, many PD1 drugs are available for cancer treatment, and more than 100 PD1 drugs are in clinical trials. However, the question of how to screen sensitive patients and predict the efficacy of immunotherapy remains unresolved. In addition, predictive biomarkers and treatment guidelines for immunotherapy of gastrointestinal malignancies have hardly been studied.
Book Synopsis New immunotherapy strategies and related therapeutic targets for gastrointestinal malignancies by : Chi Chun Wong
Download or read book New immunotherapy strategies and related therapeutic targets for gastrointestinal malignancies written by Chi Chun Wong and published by Frontiers Media SA. This book was released on 2024-03-13 with total page 204 pages. Available in PDF, EPUB and Kindle. Book excerpt: Currently, the treatment options for gastrointestinal malignancies mainly include surgery, chemotherapy, radiotherapy, and molecular targeted therapy, etc. Drug therapy is one of the main treatments for patients with advanced stages, but the efficacy of chemotherapy seems to have reached a plateau, and the progress of traditional molecular targeted therapy is relatively slow. In addition, the benefits of the current chemotherapy combined with targeted therapy for patients with advanced stages of gastrointestinal malignancies are still not satisfactory. Tumor immunotherapy is an emerging therapeutic approach and is a current research hotspot, and there are hopes that immunotherapy can help further improve the prognosis and quality of life for patients with gastrointestinal malignancies. At the same time, potential targets of immunotherapeutic drugs and prognostic biomarkers for gastrointestinal malignancies have been less studied than other common cancers, such as lung cancer. Prognostic biomarker studies are the beginning of exploring new drug targets and revealing potential mechanisms of tumor progression. Immunotherapies, particularly PD1 or PD-L1 antagonists, have demonstrated effective therapeutic efficacy against various types of cancer. To date, many PD1 drugs are available for cancer treatment, and more than 100 PD1 drugs are in clinical trials. However, the question of how to screen sensitive patients and predict the efficacy of immunotherapy remains unresolved. In addition, predictive biomarkers and treatment guidelines for immunotherapy of gastrointestinal malignancies have hardly been studied.
This book is about the manipulation of the immune system as a therapeutic approach to gastrointestinal cancer and its clinical applications, exploring therapeutic approaches which might be taken under the broad banner of immunotherapy. Starting by introducing concepts of modern immunology, the clinical applications of immunotherapy are then discussed. The reader will learn about the three broad classes of immune therapeutic agents: cell-based treatment; antibody therapy; cytokine application and the key effector cells and mechanisms which might cause tumour rejection. The reverse side of this equation, the genetic and molecular mechanisms which the tumour can use to escape immune control and regulation, is also discussed. Through reviewing the most up-to-date evidence, this volume provides an overview of the important scientific lessons learned from past failure of immunotherapeutics in the clinic and highlights more positive recent data, coupled to practical guidelines for clinical usage. Written by a team of worldwide experts, this is an indispensable guide for medical oncologists, surgical oncologists, radiation therapists, pharmacists, oncology nurse specialists.
Book Synopsis Immunotherapy for Gastrointestinal Cancer by : David Kerr
Download or read book Immunotherapy for Gastrointestinal Cancer written by David Kerr and published by Springer. This book was released on 2017-01-02 with total page 252 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is about the manipulation of the immune system as a therapeutic approach to gastrointestinal cancer and its clinical applications, exploring therapeutic approaches which might be taken under the broad banner of immunotherapy. Starting by introducing concepts of modern immunology, the clinical applications of immunotherapy are then discussed. The reader will learn about the three broad classes of immune therapeutic agents: cell-based treatment; antibody therapy; cytokine application and the key effector cells and mechanisms which might cause tumour rejection. The reverse side of this equation, the genetic and molecular mechanisms which the tumour can use to escape immune control and regulation, is also discussed. Through reviewing the most up-to-date evidence, this volume provides an overview of the important scientific lessons learned from past failure of immunotherapeutics in the clinic and highlights more positive recent data, coupled to practical guidelines for clinical usage. Written by a team of worldwide experts, this is an indispensable guide for medical oncologists, surgical oncologists, radiation therapists, pharmacists, oncology nurse specialists.
Book Synopsis Novel Approaches to Target the Immune System in Gastrointestinal Cancers by : Gianluigi Giannelli
Download or read book Novel Approaches to Target the Immune System in Gastrointestinal Cancers written by Gianluigi Giannelli and published by Frontiers Media SA. This book was released on 2022-01-31 with total page 151 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Immunotherapy based on immune checkpoint molecules is gradually becoming an important treatment strategy for gastrointestinal tumours and inflammation. This Research Topic will focus on the role of immune checkpoint molecules in gastrointestinal inflammation and tumours, the latest progress in the corresponding regulatory mechanisms. Meanwhile, this topic explores the similarities and differences of different immune checkpoint molecules in tumours such as gastric cancer and colorectal cancer and inflammatory diseases such as inflammatory bowel diseases, intestinal-related sepsis, and peritoneal infection. Furthermore, not only limited to oncology treatment, the application of immune checkpoint inhibitors extends to inflammatory diseases of the gastrointestinal tract. Thus, immunotherapy targeting immune checkpoint molecules offers great promise for the treatment of gastrointestinal disorders. Immunotherapy is one of the most cutting-edge fields in the current treatment of gastrointestinal diseases. Immune checkpoint inhibitors have been gradually applied in the clinical treatment of gastrointestinal tumours and have been gradually explored in gastrointestinal inflammatory diseases. However, whether the expression of different immune checkpoint molecules affects the selection of immune checkpoint molecular inhibitors, how to combine different immune checkpoint molecular inhibitors, and how to screen outpatients responsive to immune checkpoint molecular inhibitors in urgent scientific questions to be addressed.
Book Synopsis The Role of Immune Checkpoints in Gastrointestinal Diseases by : Qi Yang
Download or read book The Role of Immune Checkpoints in Gastrointestinal Diseases written by Qi Yang and published by Frontiers Media SA. This book was released on 2023-08-24 with total page 127 pages. Available in PDF, EPUB and Kindle. Book excerpt: Immunotherapy based on immune checkpoint molecules is gradually becoming an important treatment strategy for gastrointestinal tumours and inflammation. This Research Topic will focus on the role of immune checkpoint molecules in gastrointestinal inflammation and tumours, the latest progress in the corresponding regulatory mechanisms. Meanwhile, this topic explores the similarities and differences of different immune checkpoint molecules in tumours such as gastric cancer and colorectal cancer and inflammatory diseases such as inflammatory bowel diseases, intestinal-related sepsis, and peritoneal infection. Furthermore, not only limited to oncology treatment, the application of immune checkpoint inhibitors extends to inflammatory diseases of the gastrointestinal tract. Thus, immunotherapy targeting immune checkpoint molecules offers great promise for the treatment of gastrointestinal disorders. Immunotherapy is one of the most cutting-edge fields in the current treatment of gastrointestinal diseases. Immune checkpoint inhibitors have been gradually applied in the clinical treatment of gastrointestinal tumours and have been gradually explored in gastrointestinal inflammatory diseases. However, whether the expression of different immune checkpoint molecules affects the selection of immune checkpoint molecular inhibitors, how to combine different immune checkpoint molecular inhibitors, and how to screen outpatients responsive to immune checkpoint molecular inhibitors in urgent scientific questions to be addressed.
This up-to-date, hands-on manual offers clear guidance on contouring and treatment planning for both standard and advanced radiation therapy in patients with gastrointestinal cancers and simultaneously draws together the available relevant clinical data for each type of cancer with a view to driving treatment recommendations. The full range of malignancies is covered, including esophageal, gastric, pancreatic, hepatic, biliary, colon, rectal, and anal cancers and pelvic recurrences. Additional chapters are devoted to stereotactic body radiation therapy (SBRT) to the liver for metastatic disease. The management of gastrointestinal cancers with radiation therapy has become increasingly complex. Specifically, the emergence of new techniques such as SBRT and intensity-modulated radiation therapy (IMRT) has further increased the need to understand how to contour targets and organs at risk, how to perform safe treatment planning, and when to apply these technologies. In this context, Radiation Therapy for Gastrointestinal Cancers represents an ideal reference for both established clinical radiation oncologists and radiation oncology residents.
Book Synopsis Radiation Therapy for Gastrointestinal Cancers by : Theodore Hong
Download or read book Radiation Therapy for Gastrointestinal Cancers written by Theodore Hong and published by Springer. This book was released on 2017-02-13 with total page 245 pages. Available in PDF, EPUB and Kindle. Book excerpt: This up-to-date, hands-on manual offers clear guidance on contouring and treatment planning for both standard and advanced radiation therapy in patients with gastrointestinal cancers and simultaneously draws together the available relevant clinical data for each type of cancer with a view to driving treatment recommendations. The full range of malignancies is covered, including esophageal, gastric, pancreatic, hepatic, biliary, colon, rectal, and anal cancers and pelvic recurrences. Additional chapters are devoted to stereotactic body radiation therapy (SBRT) to the liver for metastatic disease. The management of gastrointestinal cancers with radiation therapy has become increasingly complex. Specifically, the emergence of new techniques such as SBRT and intensity-modulated radiation therapy (IMRT) has further increased the need to understand how to contour targets and organs at risk, how to perform safe treatment planning, and when to apply these technologies. In this context, Radiation Therapy for Gastrointestinal Cancers represents an ideal reference for both established clinical radiation oncologists and radiation oncology residents.
Book Synopsis Gastrointestinal Tumor Heterogeneity and Related Anti-Cancer Strategies by : Rui Liao
Download or read book Gastrointestinal Tumor Heterogeneity and Related Anti-Cancer Strategies written by Rui Liao and published by Frontiers Media SA. This book was released on 2022-06-15 with total page 174 pages. Available in PDF, EPUB and Kindle. Book excerpt:
The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer
Book Synopsis SITC’s Guide to Managing Immunotherapy Toxicity by : Marc S. Ernstoff, MD
Download or read book SITC’s Guide to Managing Immunotherapy Toxicity written by Marc S. Ernstoff, MD and published by Springer Publishing Company. This book was released on 2019-03-15 with total page 250 pages. Available in PDF, EPUB and Kindle. Book excerpt: The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer
